A5009133064- Mesenchymal stem cell research
- Hematopoietic Stem Cell Transplantation
- Tissue Engineering and Regenerative Medicine
- Virus-based gene therapy research
- Organ Transplantation Techniques and Outcomes
- CAR-T cell therapy research
- Transplantation: Methods and Outcomes
- Bone and Joint Diseases
- Oral health in cancer treatment
- Immunotherapy and Immune Responses
- Orthopaedic implants and arthroplasty
- Cancer Cells and Metastasis
- Cancer Diagnosis and Treatment
- Anorectal Disease Treatments and Outcomes
- Herpesvirus Infections and Treatments
- Inflammatory Bowel Disease
- Bone fractures and treatments
- Hip disorders and treatments
- Neonatal Respiratory Health Research
- Xenotransplantation and immune response
- Immune Cell Function and Interaction
- Stoma care and complications
- Tendon Structure and Treatment
- Neuroblastoma Research and Treatments
- Hematological disorders and diagnostics
Centre Hospitalier Universitaire de Liège
2011-2025
University of Liège
2015-2024
Laboratoire de Génétique Cellulaire
2022
Bone Therapeutics
2019
Clinical Orthopaedics and Related Research
2019
German Institute for Global and Area Studies
2017
de Duve Institute
2013
UCLouvain
2013
KU Leuven
2013
Recent studies have suggested that coinfusion of mesenchymal stem cells (MSCs) the day hematopoietic cell transplantation (HCT) might promote engraftment and prevent graft-versus-host disease (GVHD) after myeloablative allogeneic HCT. This prompted us to investigate in a pilot study whether MSC infusion before HCT could allow nonmyeloablative (NMA) (a transplant strategy based nearly exclusively on graft-versus-tumor effects for tumor eradication) from HLA-mismatched donors be performed...
Mesenchymal stromal cells (MSC) are largely investigated in clinical trials aiming to control inappropriate immune reactions (GVHD, Crohn's disease, solid organ transplantation). As the percentage of MSC precursors bone marrow is very low, these must be expanded vitro obtain therapeutic cell doses. We describe here constitution an allogeneic human third-party bank from screened healthy volunteer donors compliance with quality specifications and ISCT-release criteria report follow-up...
Many studies have drawn attention to the emerging role of MSC (mesenchymal stem cells) as a promising population supporting new clinical concepts in cellular therapy. However, sources from which these cells can be isolated are still under discussion. Whereas BM (bone marrow) is presented main source MSC, despite invasive procedure related this source, possibility isolating sufficient numbers UCB (umbilical cord blood) remains controversial. Here, we present results experiments aimed at UCB,...
<h3>Background & Aims</h3> Mesenchymal stromal cell (MSC) infusion could be a means to establish tolerance in solid organ recipients. The aim of this prospective, controlled, phase I study was evaluate the feasibility, safety and tolerability single MSCs liver transplant <h3>Methods</h3> Ten recipients under standard immunosuppression received 1.5–3×10<sup>6</sup>/kg third-party unrelated on postoperative day 3±2, were prospectively compared control group ten As primary endpoints, MSC...
Mesenchymal stromal cells (MSCs) have potent immunomodulatory properties that make them an attractive tool against graft-versus-host disease (GVHD). However, despite promising results in phase I/II studies, bone marrow (BM-) derived MSCs failed to demonstrate their superiority over placebo the sole III trial reported thus far. from different tissue origins display characteristics, but therapeutic benefits never been directly compared GVHD. Here, we impact of BM-, umbilical cord (UC-), and...
Following European regulation 1394/2007, mesenchymal stromal cell (MSCs) have become an advanced therapy medicinal product (ATMP) that must be produced following the good manufacturing practice (GMP) standards. We describe upgrade of our existing clinical-grade MSC process to obtain GMP certification. Staff organization, premises/equipment qualification and monitoring, raw materials management, starting materials, technical processes, quality controls, release, thawing infusion were...
Background Treatment of acute respiratory distress syndrome (ARDS) associated with COronaVIrus Disease-2019 (COVID-19) currently relies on dexamethasone and supportive mechanical ventilation, remains high mortality. Given their ability to limit inflammation, induce immune cells into a regulatory phenotype stimulate tissue repair, mesenchymal stromal (MSCs) represent promising therapy for severe critical COVID-19 disease, which is an uncontrolled immune-mediated inflammatory response. Methods...
Background We investigated the ability of clinical‐grade enriched human regulatory T cells ( reg) to attenuate experimental xenogeneic graft‐versus‐host disease GVHD ) induced by peripheral blood mononuclear PBMNCs ; autologous infusion in NSG mice, as well verified their inability induce when infused alone. Study Design and Methods Human reg were isolated from apheresis products with a cell separation system CliniMACS , M iltenyi B iotec GmbH using two‐step procedure (simultaneous CD 8 19...
Abstract Background and Aim Mesenchymal stem cells [MSCs] have anti-inflammatory anti-fibrotic properties could be a potential therapy for Crohn’s disease [CD] strictures. In this phase I–II pilot trial, we assessed safety efficacy of local MSC injection to treat CD Methods patients with short [less than 5 cm in length] non-passable stricture accessible by ileocolonoscopy were included. Allogenic bone-marrow derived MSCs injected the four quadrants stricture. Adverse events clinical scores...
Abstract Background Local injection of adipose tissue-derived mesenchymal stem cells [MSCs] is effective in fistulizing perianal Crohn’s disease [CD]. Less known about bone marrow-derived MSCs and little predictive factors response magnetic resonance imaging [MRI] evolution the fistulae after MSC injection. Our aims were to evaluate safety clinical outcome for CD, MRI identify associated with fistula closure. Patients methods All CD patients appropriate drainage a seton without abscess at...
Introduction Poor graft function (PGF) is a rare but serious complication of allogeneic hematopoietic cell transplantation (alloHCT). Due to their supporting properties and immune regulatory effects, multipotent mesenchymal stromal cells (MSC) could be considered good candidate help restore bone marrow (BM) niches homeostasis facilitate hematopoiesis after alloHCT. Methods We prospectively assessed the efficacy safety ex-vivo expanded BM-derived MSC from third-party donor in series 30...
Abstract Background Perianal fistulae affects 30-34% of patients with Crohn’s Disease (CD)[1]. Scarce evidences are available on the perianal fistula pathophysiology. Bone marrow-derived Mesenchymal Stem Cells (bmMSCs) local injections have been found safe and efficient for 50% CD included in a previous prospective monocentric study[2]. The present study aims at identifying potential proteins associated closure following bmMSCs injection, using biological material collected during tract...
Objectives: Significant advances have been achieved regarding the knowledge of immunoregulatory properties mesenchymal stem cells (MSC).We are currently involved in several clinical protocols evaluating these different settings including hematopoietic or solid organ transplantation, and severe refractory autoimmune disorders.Considering large number ex-vivo expanded required for (MSC dose varies from 1 to 4x10 -6 MSC/kg patient per infusion), we evaluated Quantum® device, a GMPcompliant,...
The prognosis of steroid-refractory acute graft-versus-host disease (aGVHD) remains poor and better treatments are urgently needed. Multipotent mesenchymal stromal cell (MSC)-based therapy emerged as a promising approach but response rates were highly variable across studies. We conducted multicenter prospective study assessing the efficacy 1-2 infusion(s) cryopreserved, third-party donor bone marrow-derived MSCs for treating grade II-IV or -dependent aGVHD in series 33 patients. produced...
Abstract Background In patients with nontraumatic osteonecrosis of the femoral head (ONFH), implantation bone marrow aspirate concentrate (BMAC) could delay progression and improve symptoms in pre-fracture ONFH. However, BMAC content, especially osteoblastic stem cells, have an important individual variability. An autologous cell product effect such cell-based therapy. Questions/purposes (1) Does therapy decrease likelihood to subchondral fracture or without early collapse corresponding...